By Chris Wack Immuron Ltd. said Monday that the U.S. Naval Medical Research Center has received approval from the U.S. Food and Drug Administration to proceed with the clinical evaluation of a. | May 8, 2023
By Chris Wack Immuron Ltd. shares were up 45% to $2.71 after the company said that the U.S. Naval Medical Research Center has received approval from the U.S. Food and Drug Administration to. | May 8, 2023
MELBOURNE, Australia, May 02, 2023 Immuron Limited , an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic. | May 2, 2023
MELBOURNE, Australia, April 19, 2023 Immuron Limited , an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic. | April 19, 2023
MELBOURNE, Australia, April 11, 2023 Immuron Limited , an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic. | April 11, 2023